Kidney Cancer Trial, Recruiting NCT06336187 Sponsor: Azienda Ospedaliero Universitaria Maggiore della Carita Condition: Kidney Cancer
Back to Kidney Cancer

Kidney Cancer Trial, Recruiting

NCT06336187
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older (male or female)
  • A small solid mass (less than 4 cm) was found on your kidney unexpectedly during an imaging scan such as an ultrasound, CT, or MRI
  • A tissue sample (needle biopsy) has confirmed that the mass is a type of kidney cancer called renal cell carcinoma (RCC)
  • You are not currently receiving active treatment for your kidney mass, either because of older age, other health conditions, or a personal choice to avoid active treatment
  • You are willing to sign a consent form agreeing to take part in the study
  • You are willing to undergo a needle biopsy of the tumor and attend regular follow-up appointments as required by the study

Who may not be able to join:

  • Your kidney tumor has been found to be a different type of cancer, such as a sarcoma or lymphoma, rather than renal cell carcinoma
  • Your cancer has already spread to other parts of your body at the time of diagnosis
  • You are experiencing symptoms directly caused by the kidney tumor
  • You have a known inherited genetic condition that is linked to kidney cancer, such as Von Hippel-Lindau disease, Birt-Hogg-Dubé syndrome, or Hereditary Leiomyomatosis and Renal Cell Cancer (confirm with trial site)
  • You take blood-thinning or anti-clotting medications that cannot be safely stopped temporarily, making a needle biopsy too risky
  • The location of your tumor or its very small size makes it unsuitable for a needle biopsy
  • You are currently receiving systemic treatment (such as chemotherapy or immunotherapy) for a different type of cancer
  • Your expected life expectancy is less than one year

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 0321373201

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Azienda Ospedaliero Universitaria Maggiore della Carita
Registry
ClinicalTrials.gov
Start date
1 June 2018
Est. completion
1 December 2024

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Overall Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov